Priority 16 from the Myeloma (Canada) PSP
|UNCERTAINTY: How can we prevent and/or manage the neuropathy associated with myeloma and its treatment? (JLA PSP Priority 16)
|JLA question ID
|Peripheral neuropathy can occur as a result of myeloma and its treatment. A common side-effect of myeloma treatment, neuropathy warranted its own indicative questions because it can also occur as a result of the disease (in the abence of treatment) and because of the volume of responses associated with it. Participants would like new ways to prevent, reduce, or manage neuropathy and new treatments that do not have this side-effect.
No evidence identified
|Health Research Classification System category
|Cancer and neoplasms
|Extra information provided by this PSP
|Original uncertainty examples
|chemo that was less prone to neuropathy ~ How to prevent and/or treat chemo driven peripheral neuropathy. ~ The biggest problem with current treatments is peripheral neuropathy. What is the best way to avoid this. ~ How can we stop the neuropathy that results from Chemo therapy? ~ Is there anything a patient can do to help alleviate the symptoms of neuropathy in the feet and hands. ~ Vitamin B supplementation to help with Peripheral Neuropathy? ~ Treatment of neuropathy, how to reduce it ~ Do vitamins really help decrease or prevent neuropathy?
|Please see the PSP Engagement Summary on the JLA website
|PSP unique ID
|Total number of uncertainties identified by this PSP.
|59 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
|Date of priority setting workshop
|28 April 2021